NASDAQ:THOR Synthorx (THOR) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free THOR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$67.99▼$67.9950-Day Range$67.99▼$67.9952-Week Range$11.05▼$71.90VolumeN/AAverage Volume474,507 shsMarket Capitalization$2.20 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Synthorx alerts: Email Address Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Synthorx Stock (NASDAQ:THOR)Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.Read More Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him THOR Stock News HeadlinesMarch 21, 2024 | seekingalpha.comDesign Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | insidermonkey.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call TranscriptApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 14, 2024 | finance.yahoo.comEndeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial OfficerDecember 19, 2023 | finance.yahoo.comEndeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. to Board of DirectorsFebruary 16, 2023 | uk.finance.yahoo.comBiosimilar Interleukins Global Market Report 2023October 4, 2022 | uk.finance.yahoo.comImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors - Yahoo Finance UKSeptember 14, 2022 | businesswire.comCapstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering - Business WireApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.July 19, 2022 | businesswire.comMedikine Initiates First Clinical Trial of its Lead Program, an Interleukin-7 Mimetic, Under Management Team with Expertise in Next-Generation Cytokine Drug Discovery and Development - Business WireJune 17, 2022 | streetinsider.comForm SC 14D9 Turning Point Therapeuti Filed by: Turning Point Therapeutics, Inc. - StreetInsider.comJune 9, 2022 | seekingalpha.comVBK: Why Growth Investors Should Avoid The Small-Caps (NYSEARCA:VBK) - Seeking AlphaJune 2, 2022 | finance.yahoo.comElevateBio Announces Jill M. Mooney, Ph.D., Joins as Senior Vice President of Research and Development - Yahoo FinanceApril 30, 2022 | streetinsider.comForm DEF 14A Janux Therapeutics, Inc. For: Jun 14 - StreetInsider.comApril 29, 2022 | nasdaq.comU.S. Stocks Pull Back Sharply, Contributing To Nasdaq's Worst Month Since 2008 - NasdaqApril 29, 2022 | fool.comSanofi (SNY) Q1 2022 Earnings Call Transcript - The Motley FoolApril 4, 2022 | finance.yahoo.comGlobal Immune Checkpoint Inhibitors Market Size, Share & Industry Trends Analysis Report By Application, By Type, By Regional Outlook and Forecast, 2021 - 2027 - Yahoo FinanceMarch 17, 2022 | streetinsider.comGennao Bio Strengthens Board of Directors with Appointments of Peter Thompson, MD, and Bradley Campbell - StreetInsider.comMarch 8, 2022 | nz.finance.yahoo.comImmuno-Oncology Drugs Global Market Report 2022March 5, 2022 | benzinga.comImmuno-Oncology Drugs Global Market Report 2022 - Benzinga - BenzingaMarch 3, 2022 | benzinga.comA $28.8 Billion Global Opportunity for Synthetic Biology by 2026 - New Research from StrategyR - Benzinga - BenzingaMarch 3, 2022 | finance.yahoo.comProtein Inhibitors Global Market Report 2022 - Yahoo FinanceMarch 3, 2022 | prnewswire.comA $28.8 Billion Global Opportunity for Synthetic Biology by 2026 - New Research from StrategyR - PR NewswireMarch 3, 2022 | finance.yahoo.comImmuno-Oncology Drugs Global Market Report 2022 - Yahoo FinanceDecember 7, 2021 | businesswire.comOrbiMed Names Two New General Partners - Business WireDecember 7, 2021 | streetinsider.comOrbiMed Names Two New General Partners - StreetInsider.comNovember 13, 2021 | seekingalpha.comMedicenna Therapeutics: Treating Cancer With Immunomodulators - Seeking AlphaSee More Headlines Receive THOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synthorx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/05/2019Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:THOR CUSIP88517530 CIK350907 Webwww.synthorx.com Phone858-750-4700FaxN/AEmployees48Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.09% Return on Assets-24.62% Debt Debt-to-Equity RatioN/A Current Ratio18.87 Quick Ratio18.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.72 per share Price / Book10.12Miscellaneous Outstanding Shares32,338,000Free FloatN/AMarket Cap$2.20 billion OptionableNot Optionable BetaN/A Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Laura K. Shawver (Age 62)CEO, Pres & Director Comp: $606.48kDr. Floyd E. Romesberg (Age 54)Founder Comp: $2.68kDr. Marcos Milla Ph.D. (Age 57)Chief Scientific Officer Comp: $457.71kDr. Joseph Leveque (Age 59)Chief Medical Officer Comp: $448.76kMr. Tighe M. Reardon C.F.A. (Age 44)CPA, CPA, Acting Chief Financial Officer Key CompetitorsRocket PharmaceuticalsNASDAQ:RCKTTG TherapeuticsNASDAQ:TGTXDyne TherapeuticsNASDAQ:DYNArvinasNASDAQ:ARVNKeros TherapeuticsNASDAQ:KROSView All Competitors THOR Stock Analysis - Frequently Asked Questions How were Synthorx's earnings last quarter? Synthorx, Inc. (NASDAQ:THOR) announced its quarterly earnings data on Tuesday, November, 5th. The medical instruments supplier reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.12. What other stocks do shareholders of Synthorx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Synthorx investors own include Pfizer (PFE), Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Lululemon Athletica (LULU), Micron Technology (MU) and Novartis (NVS). When did Synthorx IPO? Synthorx (THOR) raised $100 million in an IPO on Friday, December 7th 2018. The company issued 9,100,000 shares at a price of $10.00-$12.00 per share. Jefferies, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. This page (NASDAQ:THOR) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synthorx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
